Managing Castrate- Resistant Metastatic Prostate Cancer Elisabeth I. Heath, MD Associate Professor of Medicine and Oncology Wayne State University/Karmanos.

Slides:



Advertisements
Similar presentations
ASCO G.U Lawrence H. Einhorn.
Advertisements

Más es posible: CPRC con Metástasis Óseas Sintomáticas Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Complutense.
Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.
Castrate-resistant prostate cancer (CRPC)
Natural History of Prostate Cancer Local therapy Androgen deprivation therapy (ADT) Therapies after ADT Death ADT mCRPC post- docetaxel mCRPC symptomatic.
Continuous versus Intermittent Androgen Deprivation Therapy for Prostate Cancer Robert Dreicer, M.D., M.S., FACP, FASCO Chair Dept of Solid Tumor Oncology.
Radioactive Iodine Refractory Patients : Definition and Treatment of Radioactive Iodine Refractory Thyroid Cancer Patients 방사성 옥소치료에 내성을 가진 갑상선암의 진단과 치료에.
The Challenge of Prostate Cancer Genitourinary Cancer Center at M. D. Anderson PERSONALIZED MEDICINE.
ACRIN 6687 A Phase 2, Multicenter Evaluation of 18 F-Fluoride PET as a Pharmacodynamic Biomarker for Dasatinib, a Src Kinase Inhibitor, in Men With Castration-Resistant.
Current and Emerging Biomarkers for Disease Management Elisabeth I. Heath, MD Associate Professor of Medicine and Oncology Wayne State University/Karmanos.
Ibrance® - Palbociclib
Advances in the Management of Skeletal Related Events/Bone Metastases in Prostate Cancer Robert Dreicer, M.D., M.S., FACP, FASCO Chair Dept of Solid Tumor.
HIGHLIGHTS IN THE MANAGEMENT OF BREAST CANCER
Prostate Cancer: What’s New
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Cancer vaccines are biological response modifiers. They prime the immune system to attack the cancer cells in the body. The goal is to prevent or to treat.
Introducing Apceden™.
1Stopeck A et al. Proc SABCS 2010;Abstract P
Renal Safety of Zoledronic Acid in Patients With Breast Cancer.
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
“Fighting Cancer: It’s All We Do.” ™. Restoring Quality of Life And Managing Side Effects Ulka Vaishampayan M.D. Chair, GU Multidisciplinary team Associate.
Mark Frohlich, MD, SVP and Chief Medical Officer September 25, 2008 Washington, DC 4 th Annual African American Prostate Cancer Disparity Summit.
New Developments in Cancer Treatment Dulcinea Quintana, MD.
Howard M. Sandler, MD University of Michigan Medical School
Low dose chemotherapy with insulin (Insulin Potentiation Therapy) in combination with hormone therapy for treatment of castration resistant prostate cancer.
Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.
Immunotherapeutic Approaches in Castration Resistant Prostate Cancer (CRPC) Philip Kantoff, MD Chief, Division of Solid Tumor Oncology Dana-Farber Cancer.
Annual prostate cancer symposium February 23, 2013 The Kimmel Cancer Center, Philadelphia, PA 2nd “ Novel Therapeutic Strategies for Prostate Cancer ”
Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from a Phase II Randomized Discontinuation Trial Hussain M et.
Some Current Issues in the Management of Prostate Cancer Suman Chatterjee MD.
Immunotherapy Sara Engh & Tenzin Yiga. Role of the Immune system ➔ Defends against pathogens such as bacteria, fungi, and viruses that enter the body.
Protocols for Advanced Prostate Cancer and/or Local Failure After Radical Prostatectomy Isaac Powell, MD.
Prostate Cancer Epidemiology: Estimated 2010 Total Active Disease: 773,000 Stages I-III: 508,000 Metastatic (M+): 183,000 Asymptomatic M+ CRPC Symptomatic.
Robert Dreicer, M.D., M.S., FACP Chair Dept of Solid Tumor Oncology
 Angiogenesis Signaling Cascades EGFR PI3K MAPK Nucleus Gene Activation Cell Cycle Progression M G1G1 S G2G2 Fos P P MAPK = mitogen-activated protein.
Introduction E. David Crawford, MD Professor of Surgery and Radiation Oncology University of Colorado Health Sciences Center Denver, Colorado.
Core Benefit/Risk (CR)
Potency Testing for an Autologous Cellular Immunotherapy Nicole Provost, PhD VP Product Development Dendreon Corporation February 9, 2006.
U.S. Food and Drug Administration CENTER FOR BIOLOGICS EVALUATION AND RESEARCH March 29, 2007 Sipuleucel-T BLA US Food and Drug Administration Center.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Castration-Resistant Metastatic Prostate Cancer: Novel Therapeutics Robert Dreicer, M.D., M.S., FACP Chairman Department of Solid Tumor Oncology Taussig.
Copyright © 2010, Research To Practice, All rights reserved. Vaccine Therapy for Cancer Lawrence N Shulman, MD Chief Medical Officer Senior Vice President.
A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.
CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.
Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.
Progress in Cancer Therapy Following Developments in Biopharma
REGULATORY HISTORY of ZOMETA and AREDIA JAW OSTEONECROSIS (ONJ) Oncologic Drug Advisory Committee March 4, 2005 Nancy S. Scher, M.D.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
AR-V7 Splice Variant in Prostate Cancer : Taking Centre Stage
Prof. Jae Heon, Jeong/R2 Cheol Hyun, Lee J of Clinical oncology, Vol 31 Number 4, Feb.1, 2013.
Matthew Raymond Smith, MD, PhD Professor of Medicine Harvard Medical School Program Director, Genitourinary Oncology Massachusetts General Hospital Cancer.
EVOLUZIONE DEL RAPPORTO COSTO/EFFICACIA DELLA
Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
The future of our patients already treated with first line chemotherapy First of all, I would like to take this opportunity to thank the Mediterranean.
Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand  Bannakij Lojanapiwat, Choosak Pripatnanont,
Alena Kreychman Xofigo.
SYSTEMIC THERAPY OF PROSTATE CANCER
Immunotherapy for lymphoma: The time is now
Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma  Darshil J. Shah, MD, MPH, Roxana S. Dronca,
Figure 1 Treatment-induced resistance and evolution to lineage crisis
Treatment of Advanced Disease
Treatment Overview: The Multidisciplinary Team
FDA Approvals for Systemic Treatment of Prostate Cancer in 2018
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Identifying and validating surrogate endpoints for overall survival (OS) in metastatic castration-resistant prostate cancer (CRPC) Xiaowei Guan, De Phung,
Uncovering the Right Sequence
Presentation transcript:

Managing Castrate- Resistant Metastatic Prostate Cancer Elisabeth I. Heath, MD Associate Professor of Medicine and Oncology Wayne State University/Karmanos Cancer Institute August 28, 2010

Abbreviations: AA = antiandrogen; LHRH=luteinizing hormone-releasing hormone. Typical presentation of patient as they move through the different stages. The line represents level burden of disease. Time is not proportional Under the care of ONCOLOGIST Castrate Sensitive Asymptomatic Non Metastatic Castrate Resistant Metastatic Symptomatic Local Therapy Androgen Deprivation Therapies After LHRH Agonists and AA Chemotherapy Postchemo Death ProvengeAR ModulatorsDenosumab Clinical States of Prostate Cancer Cabazitaxel

Definition of Castrate- Resistant Disease  Prostate Cancer Working Group 2 (PCWG2) PSA 2.0 ng/mL Rising PSA minimum 1 week apart LN > 2 cm used for assessment Bone scan: 2 more new lesions Howard Scher et al. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26:

Radiology April 2007 vol 243 no 1,

Androgen Deprivation Therapy  Maintain castrate levels of testosterone  ADT important in controlling castrate- sensitive population  Supportive therapy for bone health including calcium and vitamin D still indicated  Supportive therapy for symptoms of androgen suppression also indicated

Therapy for Bone Metastasis  Zoledronic acid administered IV q 4 weeks  Monitor renal function and perform close evaluations for osteonecrosis of the jaw  Prevent disease related skeletal complications including Pathological fractures Spinal cord compression Radiation therapy Surgery

Secondary Hormonal Therapy  Add anti-androgen  Subtract anti-androgen  Add ketoconazole  Add steroid  Add Diethylstilbesterol (DES)  Consider clinical trial

Immunotherapy  Sipuleucel-T (Provenge)(Dendreon) FDA approved on April 29, 2010  Approval for treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer  Provenge designed to induce an immune response against prostate cancer  First in class to be approved

Sipuleucel-T (Provenge)(Dendreon) Sipuleucel-T is composed of autologous antigen presenting cells (APCs) cultured with a fusion protein (PA2024) consisting of prostatic acid phosphatase (PAP) linked to GM-CSF Sipuleucel-T is designed to stimulate T-cell immunity to PAP PAP is expressed in the vast majority of prostate cancers but not in non-prostate tissue PA2024 provides efficient loading and processing of antigens by APCs

Cellular Immunotherapy APC takes up the antigen Recombinant Prostatic Acid Phosphatase (PAP) antigen combines with resting antigen presenting cell (APC) Fully activated, the APC is now sipuleucel-T The precise mechanism of sipuleucel-T in prostate cancer has not been established. Antigen is processed and presented on surface of the APC INFUSE PATIENT T-cells proliferate and attack cancer cells Sipuleucel-T activates T- cells in the body Active T-cell Inactive T-cell

Sipuleucel-T Manufacturing COMPLETE COURSE OF THERAPY: 3 CYCLES WEEKS 0, 2, and 4 Day 1 Leukapheresis Day 1-2 Sipuleucel-T is manufactured Day 2 Patient is infused Apheresis Center 1.5 – 2.0 ml mononuclear cells DendreonDoctor’s Office # cells infused was the maximum # of cells that could be prepared from the leukapheresis product. Median # of nucleated cells per infusion = 3.65 x 10 9 and median # of CD54+ bright cells per infusion = 7.45 x Patients premedicated 30 minutes before each infusion with Tylenol (650 mg) and Benadryl (50 mg). Sipuleucel-T or placebo administered IV over 30 minutes, and patients observed 30 minutes

IMPACT Study  Phase 3 clinical trial or Provenge compared to patient’s non-activated immune cells  512 patients in 2:1 randomization  Administered IV q 2 weeks for a total of 3 infusions  Primary endpoint: overall survival Philip W. Kantoff et al for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:

IMPACT Study  Men who received Provenge lived an average of 4.1 months longer and had a 22.5% reduction in the risk of death compared to men in control group (P=0.032, HR=0.77, [95% CI: 0.614,0.979])

IMPACT Study Philip W. Kantoff et al for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:

Current Challenges  Leukopheresis Venous access Location of center  Increasing public demand  First year only in select sites  Manufacturing centers being developed

Biologic Targets for Cancer Therapy 1. Growth Factors and Growth-Factor Receptors (HER family, VEGFR, c-kit/SCFR) 2. Signal Transduction Pathways (Ras, raf, MAPK, MEK, ERK PKC, P13K) 3. Tumor-Associated Antigens/Markers (gangliosides, CEA, MAGE, CD20, CD22) 4. Proteasome 6. Extracellular Matrix/ Angiogenic Pathways (MMPs, VEGF, integrins) 5. Cell-Survival Pathways (cyclin-dependent kinases, mTOR, cGMP, COX-2, p53, Bcl-2) HER = human epidermal growth factor receptor; MMPs = matrix metalloproteinases; SCFR = stem cell growth factor receptor. Adapted with permission from Perez-Soler R, Miller V. Presented at: New Advances in the Management of Advanced NSCLC: the Expanding Role of Targeted Therapies [live Web conference]; April 20, Tumor Cell

Targeted Agents  Compounds that target cellular pathways abnormal in cancer cells, not in normal cells  Potentially more effective and less toxic  Better understanding of genetic and biologic changes underlying prostate cancer progression has led to growing research and development of rational prostate-specific drug targets 1 1 Heath EI, Carducci MA. Hematol Oncol Clin North Am 2006 Aug;20(4):

Novel Agents  VEGF inhibitors  Src inhibitors  HSP90 inhibitors  AKT inhibitors  PI3 kinase inhibitors  MTOR inhibitors  Jak/Stat inhibitors  Encourage enrollment into clinical trials